About
Professor John Lunec, based at Newcastle University's Faculty of Medical Sciences, is a leading researcher in Molecular Oncology with over 30 years of publications focusing on the p53 tumor suppressor pathway and its interactions with oncogenic proteins like MDM2. His work spans
- Cancer Therapeutics Development
- Genomic Instability in Tumors
- Drug Resistance Mechanisms
- RNA Splicing and Retrotransposon Biology
Current research emphasizes MDM2-p53 interaction inhibitors for hematologic malignancies and sarcomas, with recent breakthroughs in
- Siremadlin and ASTX295 drug development
- Identification of SF3B1 resistance biomarkers
- Combination strategies with PARP and WEE1 inhibitors
Key collaborations exist with Professor Nicola Curtin, Professor Deborah Tweddle, and Professor Herbie Newell, with funding evident through multiple clinical trials and laboratory studies. His work has significantly impacted neuroblastoma and ovarian cancer research, establishing frameworks for
- Drug sensitivity assays
- Genotype-phenotype correlations
- Translational medicine applications
0Publications listed